HCW Biologics (NASDAQ:HCWB) versus Agios Pharmaceuticals (NASDAQ:AGIO) Head to Head Survey

HCW Biologics (NASDAQ:HCWB) and Agios Pharmaceuticals (NASDAQ:AGIO) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Earnings and Valuation

This table compares HCW Biologics and Agios Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HCW Biologics	$50,000.00	82.43	-$7.96 million	($27.60)	-0.08
Agios Pharmaceuticals	$54.03 million	37.13	-$412.78 million	($7.01)	-4.79

HCW Biologics has higher earnings, but lower revenue than Agios Pharmaceuticals. Agios Pharmaceuticals is trading at a lower price-to-earnings ratio than HCW Biologics, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares HCW Biologics and Agios Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
HCW Biologics	-83.03%	-262.33%	-34.90%
Agios Pharmaceuticals	-418.24%	-35.67%	-33.06%

Risk and Volatility

HCW Biologics has a beta of 2.37, suggesting that its stock price is 137% more volatile than the S&P 500. Comparatively, Agios Pharmaceuticals has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for HCW Biologics and Agios Pharmaceuticals, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HCW Biologics	1	0	1	0	2.00
Agios Pharmaceuticals	1	4	5	1	2.55

HCW Biologics presently has a consensus price target of $30.00, indicating a potential upside of 1,239.29%. Agios Pharmaceuticals has a consensus price target of $41.25, indicating a potential upside of 22.77%. Given HCW Biologics’ higher probable upside, equities research analysts plainly believe HCW Biologics is more favorable than Agios Pharmaceuticals.

Insider & Institutional Ownership

3.0% of HCW Biologics shares are held by institutional investors. 9.1% of HCW Biologics shares are held by insiders. Comparatively, 5.4% of Agios Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

HCW Biologics beats Agios Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About HCW Biologics

HCW Biologics Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel immunotherapies for chronic, low-grade inflammation, and age-related diseases in the United States. The company's lead products include HCW9218, which is in Phase 1 clinical chemo-refractory/chemo-resistant solid tumors with pancreatic, ovarian, breast, prostate, and colorectal cancers, as well as Phase 2 clinical trial with metastatic advanced stage ovarian cancer patients; and HCW9302 for autoimmune and proinflammatory diseases, such as alopecia areata diseases. It also develops HCW9201, a cell-based therapy that is in Phase I clinical trials for the treatment of patients with relapsed/refractory acute myelogenous leukemia; and HCW9206, an injectable immunotherapeutic to use as adjuvant for adoptive cell therapy in cancer treatment. HCW Biologics Inc. was incorporated in 2018 and is headquartered in Miramar, Florida.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.